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Experimental allergic encephalomyelitis (EAE)' isa paralytic disease that can be
induced in a number of animal species by evoking immune responses to antigens
in central nervous system (CNS) myelin, and has been studied as a model for mul-
tiple sclerosis in man (1). In Lewis rats EAE canbe induced either by immunization
with guinea pig myelin basic protein (MBP) in CFA (active EAE) or by the intrave-
nous injection into naive syngeneic recipients of spleen cells from animals with ac-
tive EAE, after in vitro culture of the splenocytes with MBP (passive EAE) . The
ascending paralysis characteristic of EAE is caused by the action ofCD4+ T lym-
phocytes that produce focal edema in the CNS by increasing vascular permeability
(2-4) . In both active and passive EAE, animals develop a transient paralysis, and
recover completely within 4-5 d of its onset (5) . The mechanisms responsible for
this spontaneous recovery, which may be similar to the acute remissions occasion-
ally seen in multiple sclerosis, are still poorly understood . Various mechanisms have
been proposed, including : suppressor cells (T lymphocytes [6-9], B lymphocytes
[10], and macrophages [11]), anti-T lymphocyte idiotype responses (12), serum sup-
pressor factors (13-16), production ofimmunosuppressive factorsby filial cells (17-19),
regulation by IFN-'Y (20), and neuroendocrine-mediatedimmunoregulation (21, 22) .
None of these mechanisms has been showndirectly to be necessary for spontaneous
recovery from EAE. It has, however, been demonstrated that CD8+ T lymphocytes
are not required (23-25) . Here we demonstrate that endogenously produced cor-
ticosterone plays an essential role in the spontaneous recovery of rats from EAE.
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Materials and Methods
Animals .
￿
Lewis strain rats, 2-4 mo old, from the specific pathogen-free animal house in
the MRC Cellular Immunology Unit, Sir William Dunn School of Pathology, were used
throughout . They were housed in a daylight cycle-controlled animal room . Animals were
This work was supported by grant number M/0/1-1/83 from the Multiple Sclerosis Society of Great
Britain and Northern Ireland .
1 Abbreviations used in this paper: ACTH, adrenocorticotropic hormone ; CNS, central nervous system ;
DTH, delayed-type hypersensitivity ; EAE, experimental allergic encephalomyelitis ; MBP, guinea pig
myelin basic protein .
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age and sex matched within each experiment. All procedures were performed under ether
anesthesia.
EAE Induction.
￿
Animals were immunized with 50 ttg guinea pig MBP (prepared as in
reference 26, but without the cation exchange chromatography step), emulsified in 100 ill
CFA (10 mg/ml mycobacterium tuberculosis H37Ra in IFA [Difco Laboratories, Detroit, MI]),
and given subcutaneously into the hind footpads (active EAE). Alternatively, the disease was
transfered to naive syngeneic recipients by spleen cells from these animals. The spleens were
taken on days 11-13 after immunization and single cell suspensions were prepared. The cells
were cultured at a concentration of 2 x 10' viable leukocytes/ml in RPMI 1640 medium
(Gibco Ltd., Paisley, Scotland) containing 5% heat-inactivated FCS, 2.5 x 10- ' M 2-ME,
and 2,ug/ml MBP for 72 h in 5% COz in air at 37°C . The cells were harvested and washed
three times with PBS containing 0.2% BSA. 5 x 10' viable leukocytes were then injected
intravenously (27, 28). Animals were scored daily for clinical signs ofdisease on a scale from
0 to 5 depending on severity: 0, normal; 1, limp tail; 2, hind limb paresis; 3, unilateral hind
limb paralysis; 4, bilateral hind limb paralysis; and 5, bilateral hind limb paralysis and incon-
tinence.
Blood Cell Counts.
￿
Animals were bled from a cut in the tail between 9 :00 a.m. and 10:00
a.m . The total number ofnucleated cells per ml of blood was determined using an electronic
cell counter (Coulter Electronics Inc., Hialeah, FL) and differential counts were done on
Giemsa-stained smears (100 cells were counted on each smear).
CorticosteroneMeasurement.
￿
Animals were caged in pairs. Between 9:00 a.m. and 10:00 a.m .
both animals in the cage were anesthetized simultaneously and bled from a cut in the tail
within 2 min. This procedure has been reported not to elevate blood steroid levels significantly
within this time interval (29) . The level of corticosterone in the serum was determined by
RIA (30) using a rabbit antiserum raised against corticosterone 21 hemisuccinate conjugated
to BSA (Sigma Chemical Co., St. Louis, MO). This antiserum, which was a gift from Dr.
C. Kenyon, MRC Blood Pressure Unit, Western Infirmary, Glasgow, shows a 717o crossreac-
tion with progesterone and 6% crossreaction with deoxycorticosterone (C. Kenyon, personal
communication) .
Adrenalectomy and Steroid Replacement.
￿
Animals were bilaterally adrenalectomized or sham
adrenalectomized by blunt dissection through a single dorsal incision. Animals were checked
at postmortem for residual adrenal tissue, which was never found. Adrenalectomized animals
(and the controls) were given 0.9% saline to drink. Replacement steroid therapy was given
by inserting implants ofcorticosterone mixed with cholesterol (Sigma Chemical Co.) in varying
proportions, subcutaneously in the flank (31) . All of the steroid pellets used weighed 100 mg
at the start of the experiment and had a uniform shape.
Delayed-type Hypersensitivity (DTH).
￿
Spleens were removed from animals immunized with
100 Pg OVA (Sigma Chemical Co.) in FCA 11 d previously and cells were cultured as for
adoptive transfer of EAE, but with 40 Fcg/ml- ' OVA instead of MBP. 5 x 10' viable leuko-
cytes were injected intravenously into syngeneic recipients 14 d after immunization with MBP
in FCA, FCA only, or physiological saline. 2 d later each animal was injected subcutaneously
in one ear with 40 hg OVA in 20 u1 PBS, and in the contralateral ear with 40 hg BSA in
20 1A PBS. 48 h later, the thickness of each ear was measured in triplicate using a "Quick-
tester" micrometer gauge (H. C. Kroplin, Federal Republic of Germany) and a mean score
for each ear was determined (2).
Results
Animals with EAEAre Lymphopenic.
￿
Spontaneous recovery from EAE presumably
involves a shut down in the activity of the cells that cause the pathology in the CNS,
and possibly a block in the generation of these cells or their traffic to the CNS. In
active EAE the effector cells that are generated in the lymph nodes draining the
site of immunization (hind footpads) must enter the bloodstream via the thoracic
duct to reach the CNS (32) . When the output of cells from the thoracic ducts of
animals immunized with MBP in CFA was studied, it was found that the traffic ofMACPHEE ET AL .
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cells into the blood from the thoracic duct was reduced fourfold during the time
when the animals were paralyzed (Table 1) . The relative proportions of cell subsets
present, defined by labeling with mAbs and flow cytofluorimetry, did not change
with time (data not shown) . However, because the thoracic duct is the main source
of lymphocytes entering the blood (32), it was anticipated that this fall would be
accompanied by a peripheral lymphopenia . Table I shows that in both active and
passive EAE there was a fall in the PBL count, similar in magnitude to the drop
in thoracic duct lymphocyte output . Fig . 1 shows the changes in peripheral blood
leukocyte counts with time after immunization with MBP in CFA . Lymphocyte counts
were normal before and after clinical disease but were markedly depressed during
the episode of paralysis . Circulating neutrophil numbers increased by three- to fourfold
within 5 d of immunization with MBP in CFA (as has been reported previously
[33]), a change which was also seen in animals given the adjuvant only (data not
shown) . During EAE neutrophilnumbers fell to normal levels but were again elevated
after recovery. This temporary reversal of the neutrophilia was not seen in animals
immunized with FCA only. Another lymphoid compartment that was depleted of
cells during EAE was the spleen (Table 1) . The spleens of animals immunized with
OVA in FCA were also hypocellular but not to such a degree .
Rats with EAE Have Elevated Serum Levels of Corticosterone .
￿
In rats corticosterone
is known to cause lymphopenia and changes in lymphocyte traffic (34, 35). Accord-
ingly, a series of experiments was carried out to determine the serum level of this
hormone in rats developing EAE . The results, shown in Fig. 2, demonstrate that
animals with signs of the disease had markedly elevated levels of the hormone, the
increase occurring just before the onset ofparalysis with its peak at the time ofmax-
imum clinical disease . In both active and passive EAE, animals started to recover
at the time when corticosterone levels were maximal . As the severity of disease declined
so did the amount of steroid present, basal levels being measured by 20 d after im-
munization in active EAE or 8 d after cell transfer in passive EAE . In active EAE
347o (67 of 195) of the animals suffered from a second mild episode of paralysis
(this was never seen in passive EAE) . The onset of this relapse correlated well with
the return ofnormal serum corticosterone levels, always occurring at 22-25 d after
immunization . This single relapse at this time has also been reported elsewhere (36,
37) and it has been shown that adrenalectomy during recovery from EAE accelerates
the onset of this. relapse (21) .
A criticism that could be made ofmeasurement of steroid levels by bleeding seri-
ally under ether anesthesia is that the stress ofbleeding is the most important factor
in raising steroid production . To confirm that the elevated steroid levels were not
an anesthetic stress artifact, animals were immunized withMBP in FCA and caged
individually. They were bled by decapitation without anesthesia within 20 s ofhan-
dling . The mean corticosterone level in four animals bled on day 7 after immuniza-
tion was 6.1 ± 4.9 nM, and in unimmunized controls bled on the same day the
value was 2 .2 t 2.0 nM . Of four immunized animals bled on day 14, two showed
clinical signs of paralysis with serum corticosterone levels of 259 nM and 316nM
and two had no clinical signs with corticosterone levels of 1.7 and 20.7 nM . Unim-
munized controls on day 14 had corticosterone levels below the threshold of detec-
tion ofthe assay. Comparing these results with those illustrated in Fig . 2, it is evident
that repeated episodes ofanesthesia and bleeding did induce some elevation in serum434
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21
0
FttsUxr . 1 . Peripheral blood
white cell counts in EAE . On
day 0 groups of four animals
were immunized with 50 wg
MBP in FICA or 100 Al saline
(controls) . The animals were
bled from a cut in the tail be-
tween 9:00a.m . and 10:00a.m .
and the total number of nu-
cleated cells per ml of blood
was determined using an elec-
tronic cell counter (Coulter
Electronics Inc.) . Differential
counts were done on Giemsa-
stained smears. This experi-
ment has been repeated twice
with similar results .
corticosterone, but that this effect did not account for the very high levels found
in animals with EAE .
Adrenalectomized Animals Do not Recoverfrom EAE.
￿
To determine whether the in-
crease in endogenous corticosterone production in EAE was essential for recovery
from the disease, animals were bilaterally adrenalectomized 3 d before immuniza-
tion or cell transfer, and given subcutaneous steroid implants to maintain normal
resting serum corticosterone levels . In both actively and passively induced EAE,
adrenalectomized animals showed clinical signs earlier than sham-operated controls
and always died (Fig. 3) . Disease developed very rapidly in adrenalectomized rats
so that an animal showing only a limp tail at one time point could be severely para-
lyzed 12 h later . For this reason the terminal clinical scores for animals that died
overnight are not known . However, rats that were observed with terminal disease
were always severely paralyzed . Histological examination of the spinal cords ofthese
animals showed inflammatory changes typical ofEAE . In pilot experiments the main-
tenance dose of corticosterone was not given and 8 of 10 animals immunized with
MBP in FCA died within 48 h of immunization . These animals had much more
severe footpad edema than sham-adrenalectomized controls and it is likely that death
was due to susceptibility to the lethal effects ofIL-1 andTNF (produced afterimmu-
nization with the adjuvant) subsequent to adrenalectomy, as was recently reported (38) .
Steroid Replacement Therapy Restores RecoveryfiomEAE in AdrenalectomizedAnimals .
￿
Hav-
ing demonstrated an essential role for the adrenal gland in preventing fatalities due
to EAE, it remained to be shown that it mediated its protective effect by the produc-
tion of increased levels of serum corticosterone rather than by the release of other
corticosterond hormones, or hormones from the adrenal medulla . To address this
point steroid levels in adrenalectomized rats were manipulated by subcutaneous cor-
ticosterone implants . Animals were either adrenalectomized or sham operated as
above and maintenance steroid implants were inserted 3 d before immunization (see
above) followed by an extra subcutaneous implant ofvarying corticosterone content436 RECOVERY FROM EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS
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￿
Adrenalectomy prevents recovery fromEAE. Active RAE was induced by immuniza-
tion with 50 ,ug MBP in FGA on day 0. For passive RAE spleen cells from MBPtFCA-primed
donors were cultured in vitro withMBP and 5 x 10' cells were injected intravenously into naive
recipients on day 0 . Animals were bilaterally adrenalectomized or sham operated 3 d before im-
munization or cell transfer, normal basal levels of serum corticosterone being maintained in
adrenalectomized rats by subcutaneous steroid implants . For activeRAE there were nine control
animals and 10 adrenalectomized . For passive RAE there were five control animals and three
adrenalectomized . The mean clinical scores apply only to surviving animals.
9 d after immunization (the time at which steroid levels in intact animals started
to rise) (Fig. 4) . When serum corticosterone levels similar to those produced en-
dogenously in EAE were achieved, the animals either suffered from a single episode
of paralysis from which they recovered completely or, in the case of one animal,
failed to develop clinical signs ofEAE (Fig. 4 c) . If lower levels were achieved the
animals still died (Fig . 4, a and b) and at higher levels the disease was suppressed
in all cases (Fig . 4 d) .
In a second series ofexperiments using steroid replacement, the additional 100%
corticosterone pellet was inserted on the daywhen animals first showed definite clin-
ical signs of disease (a score >I) rather than on day 9. When steroids were given
at this latertime 2 :4 animals showed clinical signs and recovered and twodied (Fig. 5).
In all of the above experiments steroid-treated adrenalectomized animals that re-
covered fromEAEwere observed at least until day30 afterimmunization and showed
no deterioration in condition, except for one animal in Fig. 4 dthat died unaccount-
ably, but did not have signs of paralysis .
In the adrenalectomized animalsshownin Fig . 4, a steep rise in serum corticosterone
was seen either just before death (Figs. 4 a and 5 a), or when clinical disease was
observed (Fig . 4c) . At postmortem these animals were confirmedto haveno residual
adrenal tissue and the subcutaneous steroid pellets had not broken up, thus ruling
out these two possible sources of increased levels ofserum corticosterone. An alter-
native explanation could be achange in thepharmacokinetics ofcorticosterone due
to the acute retention of urine, with subsequent hydronephrosis seen in male rats
with EAE (21, and our own observations) .
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The effect of corticosterone therapy in adrenalectomized animals . Animals were
adrenalectomized and given a 25% corticosterone in cholesterol implant (25 mg corticosterone
in 75 tng cholesterol) subcutaneously to maintain normal basal steroid levels, 3 d before immuni-
zation with 50 Wg MBP in FCA (day 0) . Additional implants of the same size with increasing
corticosterone content were inserted on day 9 after immunization, the time at which steroid levels
started to rise in control animals (Fig. 2) . The mean clinical scores apply only to surviving animals .
DTHResponses to OVAAre Inhibited in Animals with EAE .
￿
The immunosuppressive
effects of steroids are not antigen specific (34, 39), and experiments were carried
out to determine whether rats with EAE demonstrated a generalized hyporeactivity
to antigenic challenge . Table 11 shows that the adoptive transfer of DTH to OVA
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was significantly suppressed in animals with EAE . The antibody response to SRBC
in these animals was not suppressed (data not shown), a finding that is not inconsis-
tent with steroid-mediated immunosuppression (39) .
Discussion
The data presented demonstrate the essential role ofendogenous corticosterone
in modulating the severity ofEAE . It is evident that the elevated levels of the hor-
mone that develop spontaneously during the course of the disease not only prevent
the disease being a lethal one, but produce a sufficient level ofimmunosuppression
to induce complete remission of clinical signs . It could be argued that the elevated
steroid levels are necessary but not sufficient for the self cure reaction to occur and
that some other immunoregulatory mechanism, involving suppressor cells or one
of the other processes listed in the introduction, play an equally essential role . Al-
though this more complex interpretation cannot be completely dismissed, the ob-
servation that rats with EAE made very depressedDTH responses to OVA indicates
that the immunosuppression does not display antigen specificity. The finding that
(b)
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TABLE II
The DTH Response to OVA Is Inhibited in EAE
Increase in ear thickness when challenged with OVA
Control
￿
FCA
￿
MBP in FCA
Exp.
￿
animals
￿
immunized
￿
immunized3 ￿p lv3*
￿
p 2v3*
1
￿
0.43 ± 0 .045 (4)
￿
0.42 ± 0 .067 (4)
￿
0.22 ± 0.07 (3)
￿
<0.01
￿
<0.02
2
￿
-
￿
0.26 ± 0 .032 (5)
￿
0.17 ± 0.080 (5)
￿
-
￿
<0.05
On day 14 after immunization 5 x 107 OVA cultured cells were transferred to each animal. 2 d later the
animals were challenged with OVA in the left ear and BSA in the right ear, and ear swelling was measured
after 48 h. The values shown are the mean difference in thickness between the left and right ears ± 1 SD.
In Exp. 1, male animals were used; and in Exp. 2, females were used, which may explain the difference
in the absolute values recorded between the experiments. The mean clinical scores for the MBP-immunized
animals on the day of cell transfer were 5 for Exp. 1, and 3.6 for Exp. 2 . ' Untreated ; 2 Immunized with
100 ttl FCA ; 3 Immunized with 50 tag MBP in FCA .
* The differences between the groups were tested for statistical significance by student's t test.
EAE can be prevented by the prior administration of corticosterone (Fig. 4) also
supports this view as does the finding that rats exposed to environmental stress de-
velop less severe paralytic signs (40). Steroids have been given successfully as chemo-
therapy in EAE (33, 41) and multiple sclerosis (42), and adrenocorticotropic hor-
mone (ACTH) has been used to suppress EAE in guinea pigs (43).
The possibility that the endogenous production of corticosterone was responsible
for recovery from EAE has been proposed previously (21), but seems not to have
gained general acceptance. Earlier studies showed that animals with EAE developed
a partial splenic and thymic atrophy, associated with adrenal hypertrophy (33). Thymic
atrophy was found to be associated with elevated levels of corticosterone in the blood
(21). These important results, while indicating that corticosterone release in EAE
was associated with changes in lymphoid tissue and with reduced blood lymphocyte
counts, did not establish that these steroid-induced changes were instrumental in
bringing about the remission of signs of paralysis .
The site of action of this steroid response is still not clear. Steroids can regulate
the immune response in a number of ways, including the inhibition of production
of IL-1 and IL-2 (44, 45), effects on lymphocyte traffic (35), and the depletion of
lymphocytes (corticosterone is lympholytic in rats) described earlier (34). Steroids,
therefore, have the capacity to inhibit the activity of effector cells in the CNS, and
to prevent the generation and supply of fresh activated cells.
Although the pathogenesis of EAE is probably not due to a DTH reaction in the
CNS (2), a DTH response does have some essential features similar to the develop-
ment of EAE; i.e., the localization of antigen-specific effector cells in a nonimmune
organ, and their activation to secrete lymphokines. As already noted, the DTH re-
sponse to an antigen not involved in EAE (OVA) was suppressed during the time
when animals were recovering from EAE and had elevated steroid levels. It has also
been reported that DTH responses to MBP are suppressed in animals with clinical
signs of EAE (46, 47), and that responses to mycobacterial purified protein deriva-
tive are also suppressed, although the data were not shown (47). Steroids are known
to interfere with the development of DTH responses at several levels (34, 35, 39,
44, 45), and it is reasonable to suggest that corticosterone modulates the course ofMACPHEE ET AL .
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EAE by interfering with the same processes . Steroids have also been shown to have
a direct effect on the permeability of the blood brain barrier (48), the breakdown
ofwhich appears to be important in the pathogenesis ofEAE (4), and it is possible
that this effect contributes to the recovery phase of EAE .
The elevated steroid levels in EAE may be due directly to the stress of the disease,
or possibly subsequent to lymphokine release in the CNS . In both this paper and
reference 21, elevated steroid levels were first recorded before animals were para-
lyzed but after the appearance of inflammation in the CNS. Several inflammatory
mediators, most notably IL-1, have been shown to be capable of increasing adrenocor-
tical steroid production by action on either the anterior pituitary, increasing the re-
lease of ACTH (49) ; or neurones in the paraventricular nucleus of the anterior
hypothalamus, by increasing the release of corticotropin releasing factor (50, 51) .
In addition lymphocytes have the capacity to produce ACTH (52), so in principal
these cells may act directly on the adrenal cortex although this action remains to
be demonstrated . EAE may therefore be an example of an autoimmune response
that is regulated by the immunoneuroendocrine feedback loop proposed by several
investigators (53-55) .
In regulation ofEAE by exogenous steroids, it appears to be important that ste-
roid levels in adrenalectomized animals rise early in the disease course as is the case
in intact animals . At levels of corticosterone that allowed 100% survival when they
were achieved before the onset of clinical signs, 2 :4 animals died when the implants
were inserted after the onset of paralysis . Such findings may have implications for
the treatment of acute exacerbations of disease in patients with multiple sclerosis .
After spontaneous recovery from actively induced EAE, animals become refrac-
tory to further attempts to induce the disease (5) . During this phase animals have
normal steroid levels, which suggests that a steroid-independent mechanism is in-
volved at this stage. There seems to be awindow of several days between the return
ofnormal resting corticosterone levels and the development of the long-term refrac-
tory state . A single second episode of paralysis is often observed at this time (36,
37) and EAE can be reinduced by immunization on days 21 and 28 after immuniza-
tion but no later than this (56) . Treatment of Lewis rats with a low dose of cyclospo-
rine A (57) or with cyclophosphamide (58) during the development ofEAE results
in a chronic relapsing and remitting disease course where animals recover spontane-
ously from each episode ofparalysis but the long-term refractory state fails to devel-
op . The finding that the long-term refractory phase does not depend on chronically
elevated levels of corticosterone and that rats treated with low doses ofimmunosup-
pressive drugs tend to relapse, provides compelling evidence that the acute recovery
from a monophasic episode ofEAE depends on a different immunoregulatory mech-
anism to that responsible for the subsequent refractory phase .
Summary
Lewis rats with experimental allergic encephalomyelitis (EAE), induced either by
the subcutaneous injection ofguinea pig myelin basic protein (MBP) or by the adoptive
transfer ofMBP-primed spleen cells, suffer from a single episode of paralysis from
which they recover spontaneously . Animals developing EAE were found to have greatly
elevated levels of corticosterone in the blood . This endogenous increase in steroid
production was accompanied by lymphopenia and depressed delayed-type hyper-442
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sensitivity responses to OVA, indicating that rats with EAE are immunosuppressed
in an antigen-nonspecific fashion. Adrenalectomized rats given subcutaneous im-
plants of corticosterone to maintain basal steroid levels invariably died when EAE
was induced. However, if the steroid replacement therapy was adjusted to mimic
the hormone levels that were observed in intact rats developing EAE, then the dis-
ease followed a nonfatal course closely resembling that seen in the nonadrenalec-
tomized controls. Replacement therapy that achieved serum corticosterone levels
slightly higher than those found in intact rats with EAE virtually suppressed the
disease completely.
It is concluded that endogenous corticosterone release in rats with EAE plays an
essential role in the spontaneous recovery that is observed in this condition . How-
ever, the subsequent refractory phase that is characteristic of rats that have recov-
ered from EAE induced by active immunization with MBP is not associated with
chronically elevated corticosterone levels. This finding is discussed in the light of
other data that suggest that unlike the spontaneous recovery, the refractory state
has an immunological basis rather than an endocrinological basis.
The authors would like to acknowledge the expert technical assistance of Mr. Steve Simmonds,
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